Gamma Medica opens design, manufacturing plant in Salem
Through the noninvasive procedure, women whose mammograms were inconclusive can opt for the MBI testing, according to Calandra. The testing is about one-third the cost of an MRI and is used for further analysis of dense breast tissue.
“The development of molecular breast imaging, and its ability to identify even small early cancers is a most welcome addition,” Hannon said. He said the devices developed by Gamma Medica provide molecular breast imaging that is simple, safe and accurate.
Gamma Medica received $16 million in financing from the health-care investment firm Psilos Group Managers this summer. The funding will allow the company to expand commercialization of the LumaGEM MBI system and a companion product, the LumaGUIDE MBI-guided biopsy module, according to Calandra.
“There is a strong medical device presence here and we are close to Boston, where there is a prevalence of medical device companies along Route 128 and around the Merrimack Valley,” he said, adding that proximity to a number of world-renowned hospitals also played a role in the decision.
“The company was looking to locate in a place where there is access to talented employees, universities and hospitals, as well as low operating costs,” Bergeron said.
Derry to NH: Take Exit 4A
Editorial: Garcia gains Lambert lies
The music spoke, she listened
ISIS beheads NH journalist